Market By Type, Industry Verticals, And Country | Forecast 2021-2028
Triton’s research report has estimated that the North American non-alcoholic steatohepatitis (NASH) biomarker market is likely to expand at a CAGR of 20.64% during the examined period 2021-2028.
Report scope can be customized per your requirements. Request For Customization
The countries reviewed in this market are:
•       United States
•       Canada
Over the years, there has been a substantial rise in the obesity rates, which is a significant factor responsible for the high prevalence of non-alcoholic fatty liver disease in the United States. As per a study by the Intermountain Healthcare researchers on the economic impact of the disease, non-alcoholic fatty liver disease affects millions of people each year, costing the healthcare sector billions of dollars. Further, it is estimated to become the most prevalent chronic liver condition, primarily because of the obesity and diabetes epidemic across the country. Additionally, NASH is anticipated to be a leading cause of liver transplantation. These are some of the factors driving the progression of the NASH biomarker market in the US over the considered period.
Non-alcoholic steatohepatitis is a severe form of non-alcoholic fatty liver disease, which refers to the inflammation of a fatty liver. Diabetes and obesity are significant risk factors for the development of non-alcoholic fatty liver disease. In Canada, obesity and diabetes levels have increased significantly in recent years. Here, the obesity rates have tripled in the past few years, contributing to the growth of the studied market. While a fatty liver is considered a benign condition, NASH is associated with ongoing liver damage and can cause liver cancer. Therefore, an increase in obesity and diabetes levels is expected to widen the scope and growth of the non-alcoholic steatohepatitis (NASH) biomarker market.
Viking Therapeutics is a biopharmaceutical company engaged in the development of therapies for metabolic and endocrine disorders. It offers clinical programs to treat conditions, such as type-2 diabetes. Besides, it develops VK0214 and VK2809 for treating fatty liver disease. The company’s R&D activities help in developing innovative therapeutics to improve patient lives. Founded in 2012, Viking Therapeutics is headquartered in California, the United States.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT
1. NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. KEY INSIGHTS
2.1.1. DEMAND FOR NASH BIOMARKERS
2.1.2. UNMET MEDICAL NEEDS
2.2. IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTE PRODUCTS
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR LANDSCAPE
2.6. KEY MARKET STRATEGIES
2.6.1.  CONTRACTS & PARTNERSHIPS
2.6.2.  BUSINESS EXPANSIONS & DIVESTITURES
2.6.3.  ACQUISITIONS & MERGERS
2.6.4.  NEW PRODUCT LAUNCHES
2.7. MARKET DRIVERS
2.7.1. RISING PREVALANCE OF NASH
2.7.2. INCREASING INCIDENCE RATE OF METABOLIC COMORBIDITIES
2.8. MARKET RESTRAINTS
2.8.1. SIDE-EFFECTS OF NASH THERAPEUTICS
2.8.2. UNAVAILABILITY OF SPECIALIZED DIAGNOSTIC TEST FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
2.9. MARKET OPPORTUNITIES
2.9.1. RISE IN AWARENESS PERTAINING TO NON-ALCOHOLIC FATTY LIVER DISEASE
3. NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY TYPE
3.1. SERUM BIOMARKER
3.2. HEPATIC FIBROSIS BIOMARKER
3.3. APOPTOSIS BIOMARKER
3.4. OXIDATIVE STRESS BIOMARKER
3.5. OTHER TYPES
4. NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY INDUSTRY VERTICALS
4.1. PHARMA & CRO INDUSTRY
4.2. DIAGNOSTIC LAB
4.3. ACADEMIC RESEARCH KEY
4.4. HOSPITAL
5. NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET – COUNTRY OUTLOOK
5.1. UNITED STATES
5.2. CANADA
6. COMPETITIVE LANDSCAPE
6.1. ALLERGAN
6.2. ASTRAZENECA
6.3. BRISTOL MYERS SQUIBB COMPANY
6.4. GENFIT SA
6.5. GILEAD SCIENCES, INC
6.6. MADRIGAL PHARMACEUTICALS
6.7. MERCK & CO
6.8. NOVARTIS AG
6.9. NOVO NORDISK
6.10. PFIZER INC
6.11. SIEMENS HEALTHINEERS
6.12. VIKING THERAPEUTICS
6.13. ZYDUS CADILA
7. RESEARCH METHODOLOGY & SCOPE
7.1. RESEARCH SCOPE & DELIVERABLES
7.1.1. OBJECTIVES OF STUDY
7.1.2. SCOPE OF STUDY
7.2. SOURCES OF DATA
7.2.1. PRIMARY DATA SOURCES
7.2.2. SECONDARY DATA SOURCES
7.3. RESEARCH METHODOLOGY
7.3.1. EVALUATION OF PROPOSED MARKET
7.3.2. IDENTIFICATION OF DATA SOURCES
7.3.3. ASSESSMENT OF MARKET DETERMINANTS
7.3.4. DATA COLLECTION
7.3.5. DATA VALIDATION & ANALYSIS
TABLE 1:Â Â Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 2:Â Â Â Â Â Â VENDOR LANDSCAPE
TABLE 3:Â Â Â Â Â Â LIST OF CONTRACTS & PARTNERSHIPS
TABLE 4:Â Â Â Â Â Â LIST OF BUSINESS EXPANSIONS & DIVESTITURES
TABLE 5:Â Â Â Â Â Â LIST OF ACQUISITIONS & MERGERS
TABLE 6:Â Â Â Â Â Â LIST OF NEW PRODUCT LAUNCHES
TABLE 7:Â Â Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 8:Â Â Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)
TABLE 9:Â Â Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
FIGURE 1:Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 2:    PORTER’S FIVE FORCES ANALYSIS
FIGURE 3:Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2020 & 2028 (IN %)
FIGURE 4:Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 5:Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 6:Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 7:Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 8:Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2028 (IN $ MILLION)
FIGURE 9:Â Â Â Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2020 & 2028 (IN %)
FIGURE 10:Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2028 (IN $ MILLION)
FIGURE 11:Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2028 (IN $ MILLION)
FIGURE 12:Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2028 (IN $ MILLION)
FIGURE 13:Â NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2028 (IN $ MILLION)
FIGURE 14:Â UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 15:Â CANADA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)